查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1606458

胃轻瘫治疗市场，按药物类别、类型、给药途径、疾病适应症、配销通路、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Gastroparesis Treatment Market, By Drug Class, By Type, By Route of Administration, By Disease Indication, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 311 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年胃轻瘫治疗市场规模为63.9043亿美元，2024年至2032年复合年增长率为4.77%。

胃轻瘫治疗市场-市场动态

全球糖尿病盛行率上升推动市场需求

由于糖尿病是胃轻瘫的主要原因，全球糖尿病病例的增加刺激了对胃轻瘫治疗的需求。国际糖尿病联盟报告称，2021年有5.37亿成年人患有糖尿病，预计到2030年这一数字将增至6.43亿。增加支持了胃轻瘫治疗的需求。然而，目前的胃轻瘫治疗侧重于症状管理而不是治癒病情，这限制了有效性并导致患者不满意。这可能会阻碍未来几年的市场成长。相反，正在进行的对胃轻瘫根本原因的研究、提高认识活动以及改进早期检测的诊断工具的进步预计将在预测期内为全球胃轻瘫治疗市场提供巨大的成长机会。

胃轻瘫治疗市场 - 主要见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 4.77% 左右的复合年增长率成长

根据药物类别细分，预计促动力药物将在 2023 年呈现最大市场份额

从类型细分来看，处方药是2023年的主导细分市场

依给药途径细分，2023年口服为主导类型

依疾病适应症细分，2023年糖尿病胃轻瘫为主导细分

从配销通路细分来看，医院药局是2023年的主导细分市场

按地区划分，北美胃轻瘫治疗市场是 2023 年的主要收入来源

胃轻瘫治疗市场-細項分析：

全球胃轻瘫治疗市场根据药物类别、类型、给药途径、疾病适应症、配销通路和地区进行细分。

依药物类别，市场分为四大类：止吐药、促动力药、质子帮浦抑制剂等。促胃动力药物对于胃轻瘫的治疗至关重要，因为它们可以增强胃肌收缩，减轻噁心等症状并改善消化。它们的功效不仅限于胃轻瘫，研究显示它们还可以帮助重症患者接受肠内营养，减少餵食不耐受。

全球胃轻瘫治疗市场依类型分为两大类：处方药和非处方药。在预测期内，处方药产业可能会主导市场。这是由于胃轻瘫盛行率不断上升以及对有效治疗的需求不断增长。处方药通常更有效，并且专门针对复杂的病情而设计，这推动了它们在医疗保健提供者和患者中的采用。

胃轻瘫治疗市场 - 地理洞察

从地理来看，该市场广泛分布于北美、拉丁美洲、欧洲、亚太地区、中东和非洲地区。这些区域根据开展业务的国家进一步划分。

胃轻瘫治疗市场-竞争格局：

胃轻瘫盛行率的日益增加正在形成一个专注于创新治疗方案的竞争格局。公司正在优先考虑研发以引入先进的疗法，包括促动力剂和饮食管理解决方案。与医疗保健专业人员和研究机构的合作可提高治疗效果并促进最新临床实践的采用。此外，透过教育活动提高认识对于改善早期诊断和患者对治疗的依从性至关重要。个人化医疗的趋势也正在兴起，允许客製化治疗计划，更好地满足个别患者的需求。

最新进展：

2024 年 6 月，专注于胃肠道治疗的生物製药公司 Renexxion Ireland Limited 的那罗那必利研究性新药申请获得 FDA 批准。这种口服药物针对胃轻瘫，这是一种导致胃排空延迟并伴随噁心和呕吐等症状的疾病，影响了美国、欧洲和澳洲的数百万人。

目录

第一章：胃轻瘫治疗市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按药物类别分類的胃轻瘫治疗市场片段
    • 按类型分類的胃轻瘫治疗市场片段
    • 依给药途径分類的胃轻瘫治疗市场片段
    • 按疾病适应症分類的胃轻瘫治疗市场片段
    • 按配销通路分類的胃轻瘫治疗市场片段
    • 按国家/地区分類的胃轻瘫治疗市场片段
    • 按地区分類的胃轻瘫治疗市场片段
  • 竞争洞察

第 3 章：胃轻瘫治疗主要市场趋势

  • 胃轻瘫治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 胃轻瘫治疗市场限制
    • 市场限制影响分析
  • 胃轻瘫治疗市场机会
  • 胃轻瘫治疗市场未来趋势

第 4 章：胃轻瘫治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：胃轻瘫治疗市场：地缘政治紧张局势升级的影响

  • COVID-19 大流行的影响
  • 俄罗斯-乌克兰战争的影响
  • 中东衝突的影响

第 6 章：胃轻瘫治疗市场格局

  • 2023 年胃轻瘫治疗市占分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：胃轻瘫治疗市场 - 依药物类别

  • 概述
    • 按药物类别分類的细分市场份额分析
    • 止吐药
    • 促动力剂
    • 质子帮浦抑制剂
    • 其他的

第 8 章：胃轻瘫治疗市场 - 按类型

  • 概述
    • 按类型分類的细分市场占有率分析
    • 处方药
    • 非处方药

第 9 章：胃轻瘫治疗市场 - 按给药途径

  • 概述
    • 按给药途径分類的细分市场份额分析
    • 鼻腔
    • 注射剂
    • 口服

第 10 章：胃轻瘫治疗市场 - 依疾病适应症

  • 概述
    • 按疾病适应症分類的细分市场份额分析
    • 特发性胃轻瘫
    • 糖尿病胃轻瘫
    • 术后胃轻瘫

第 11 章：胃轻瘫治疗市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 网路药局
    • 零售药局
    • 医院药房

第 12 章：胃轻瘫治疗市场 - 依地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美胃轻瘫治疗主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按药物类别）
    • 北美市场规模和预测（按类型）
    • 北美市场规模与预测（按管理途径）
    • 北美市场规模与预测（按疾病适应症）
    • 北美市场规模和预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲胃轻瘫治疗主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按药物类别）
    • 欧洲市场规模与预测（按类型）
    • 欧洲市场规模与预测（按管理途径）
    • 欧洲市场规模与预测（按疾病适应症）
    • 欧洲市场规模和预测（按配销通路）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区胃轻瘫治疗主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模和预测（按药物类别）
    • 亚太地区市场规模与预测（按类型）
    • 亚太地区市场规模与预测（依管理途径）
    • 亚太地区市场规模与预测（依疾病适应症）
    • 亚太地区市场规模和预测（按配销通路）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲胃轻瘫治疗主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按药物类别）
    • 拉丁美洲市场规模与预测（按类型）
    • 拉丁美洲市场规模与预测（按管理途径）
    • 拉丁美洲市场规模与预测（按疾病适应症）
    • 拉丁美洲市场规模和预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲胃轻瘫治疗主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按药物类别）
    • 中东和非洲市场规模及预测（按类型）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模及预测（依疾病指示）
    • 中东和非洲市场规模及预测（按配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 13 章：主要供应商分析-胃轻瘫治疗产业

  • 竞争仪表板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • Medtronic plc
    • Abbott Laboratories
    • Salix Pharmaceuticals, Inc.
    • Kimberly-Clark Corporation
    • CR Bard, Inc
    • Boston Scientific Corporation
    • Janssen Global Services LLC
    • Alfa Wassermann SPA
    • AbbVie Inc.
    • Evoke Pharma
    • Cardinal Health, Inc.
    • Rhythm Pharmaceuticals, Inc.
    • GlaxoSmithKline Plc
    • Bausch Health
    • Neurogastrx, Inc.
    • Theravance Biopharma
    • AstraZeneca Plc
    • Cipla Limited
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Limited
    • The Takeda Pharmaceutical Company Ltd.
    • Processa Pharmaceuticals, Inc.
    • Vanda Pharmaceuticals, Inc.
    • Otsuka Holdings Co. Ltd.
    • ANI Pharmaceuticals, Inc.
    • CinDome Pharma, Inc.
    • PTC Therapeutics
    • Ironwood Pharmaceuticals, Inc.
    • Others

第 14 章：360 度分析师视角

第 15 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4173

REPORT HIGHLIGHT

Gastroparesis treatment market size was valued at USD 6,390.43 Million in 2023, expanding at a CAGR of 4.77% from 2024 to 2032.

Gastroparesis is a condition in which the stomach's ability to empty is delayed due to partial paralysis. This causes food to remain in the stomach longer than normal. The gastroparesis treatment focuses on managing delayed stomach emptying, aiming to alleviate symptoms like nausea, vomiting, and bloating. Primary approaches include prokinetic agents that enhance gastric motility, antiemetics to control nausea, and dietary modifications for symptom relief. For severe cases, gastric electrical stimulation may be used. As gastroparesis is commonly linked to diabetes and is often underdiagnosed, early diagnosis and targeted treatments are essential for effective management.

Gastroparesis Treatment Market- Market Dynamics

Increasing prevalence of diabetes globally to propel market demand

As diabetes is a major cause of gastroparesis, the global increase in diabetes cases fuels demand for gastroparesis treatments. The International Diabetes Federation reports that 537 million adults were living with diabetes in 2021, with numbers projected to rise to 643 million by 2030. Besides, as gastroparesis is more common in older adults, the global increase in the aging population supports demand for gastroparesis treatment. However, current gastroparesis treatments focus on symptom management rather than curing the condition, which limits effectiveness and leads to patient dissatisfaction. This may hamper the market growth in the coming years. On the contrary, ongoing research into the underlying causes of gastroparesis, increasing awareness campaigns, and advancements in diagnostic tools to improve early detection are all expected to provide massive growth opportunities for the global gastroparesis treatment market during the forecast period.

Gastroparesis Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.77% over the forecast period (2024-2032)

Based on drug class segmentation, prokinetic drugs was predicted to show maximum market share in the year 2023

Based on type segmentation, prescription drugs was the leading segment in 2023

Based on route of administration segmentation, oral was the leading type in 2023

Based on disease indication segmentation, diabetes gastroparesis was the leading segment in 2023

Based on distribution channel segmentation, hospital pharmacies was the leading segment in 2023

On the basis of region, the North America gastroparesis treatment market was the leading revenue generator in 2023

Gastroparesis Treatment Market- Segmentation Analysis:

The Global Gastroparesis Treatment Market is segmented on the basis of Drug Class, Type, Route of Administration, Disease Indication, Distribution Channel, and Region.

The market is divided into four categories based on drug class: antiemetic drugs, prokinetic agents, proton pump inhibitors, and others. Prokinetic agents are crucial in the treatment of gastroparesis as they enhance stomach muscle contractions, alleviating symptoms like nausea and improving digestion. Their effectiveness extends beyond gastroparesis and studies have shown that they also help critical patients receiving enteral nutrition, reducing feeding intolerance.

The global gastroparesis treatment market is divided into two categories based on type: prescription drugs and over-the-counter drugs. The prescription drugs sector is likely to dominate the market during the forecast period. This is due to the rising prevalence of gastroparesis and the growing demand for effective treatments. Prescription medications are often more potent and specifically tailored to address the complexities of the condition, which drives their adoption among healthcare providers and patients.

Gastroparesis Treatment Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Gastroparesis Treatment Market- Competitive Landscape:

The increasing prevalence of gastroparesis is creating a competitive landscape focused on innovative treatment options. Companies are prioritizing research and development to introduce advanced therapies, including prokinetic agents and dietary management solutions. Collaborations with healthcare professionals and research institutions enhance treatment effectiveness and foster the adoption of the latest clinical practices. Additionally, raising awareness through educational initiatives is essential for improving early diagnosis and patient adherence to treatments. The trend towards personalized medicine is also emerging, allowing for tailored treatment plans that better address individual patient needs.

Recent Developments:

In June 2024, Renexxion Ireland Limited, a biopharmaceutical company focused on gastrointestinal treatments, has gained FDA approval for its Investigational New Drug application for naronapride. This oral drug targets gastroparesis, a disorder causing delayed stomach emptying with symptoms like nausea and vomiting, affecting millions in the U.S., Europe, and Australia.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL GASTROPARESIS TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Medtronic plc
  • Abbott Laboratories
  • Salix Pharmaceuticals, Inc.
  • Kimberly-Clark Corporation
  • C. R. Bard, Inc
  • Boston Scientific Corporation
  • Janssen Global Services LLC
  • Alfa Wassermann SPA
  • AbbVie Inc.
  • Evoke Pharma
  • Cardinal Health, Inc.
  • Rhythm Pharmaceuticals, Inc.
  • GlaxoSmithKline Plc
  • Bausch Health
  • Neurogastrx, Inc.
  • Theravance Biopharma
  • AstraZeneca Plc
  • Cipla Limited
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Limited
  • The Takeda Pharmaceutical Company Ltd.
  • Processa Pharmaceuticals, Inc.
  • Vanda Pharmaceuticals, Inc.
  • Otsuka Holdings Co. Ltd.
  • ANI Pharmaceuticals, Inc.
  • CinDome Pharma, Inc.
  • PTC Therapeutics
  • Ironwood Pharmaceuticals, Inc.
  • Others

GLOBAL GASTROPARESIS TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Antiemetic Drugs
  • Prokinetic Agents
  • Proton Pump Inhibitors
  • Others

GLOBAL GASTROPARESIS TREATMENT MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Prescription Drugs
  • Over-the-Counter Drugs

GLOBAL GASTROPARESIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Nasal
  • Injectables
  • Oral

GLOBAL GASTROPARESIS TREATMENT MARKET, BY DISEASE INDIATION- MARKET ANALYSIS, 2019 - 2032

  • Idiopathic Gastroparesis
  • Diabetes Gastroparesis
  • Post-surgical Gastroparesis

GLOBAL GASTROPARESIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Online Pharmacies
  • Retail Pharmacies
  • Hospital Pharmacies

GLOBAL GASTROPARESIS TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Gastroparesis Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Gastroparesis Treatment Market Snippet by Drug Class
    • 2.1.2. Gastroparesis Treatment Market Snippet by Type
    • 2.1.3. Gastroparesis Treatment Market Snippet by Route of Administration
    • 2.1.4. Gastroparesis Treatment Market Snippet by Disease Indication
    • 2.1.5. Gastroparesis Treatment Market Snippet by Distribution Channel
    • 2.1.6. Gastroparesis Treatment Market Snippet by Country
    • 2.1.7. Gastroparesis Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Gastroparesis Treatment Key Market Trends

  • 3.1. Gastroparesis Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Gastroparesis Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Gastroparesis Treatment Market Opportunities
  • 3.4. Gastroparesis Treatment Market Future Trends

4. Gastroparesis Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Gastroparesis Treatment Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Gastroparesis Treatment Market Landscape

  • 6.1. Gastroparesis Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Gastroparesis Treatment Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. Antiemetic Drugs
    • 7.1.3. Prokinetic Agents
    • 7.1.4. Proton Pump Inhibitors
    • 7.1.5. Others

8. Gastroparesis Treatment Market - By Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 8.1.2. Prescription Drugs
    • 8.1.3. Over-the-Counter Drugs

9. Gastroparesis Treatment Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 9.1.2. Nasal
    • 9.1.3. Injectables
    • 9.1.4. Oral

10. Gastroparesis Treatment Market - By Disease Indication

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Disease Indication, 2023 & 2032 (%)
    • 10.1.2. Idiopathic Gastroparesis
    • 10.1.3. Diabetes Gastroparesis
    • 10.1.4. Post-surgical Gastroparesis

11. Gastroparesis Treatment Market - By Distribution Channel

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 11.1.2. Online Pharmacies
    • 11.1.3. Retail Pharmacies
    • 11.1.4. Hospital Pharmacies

12. Gastroparesis Treatment Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Gastroparesis Treatment Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Gastroparesis Treatment Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.10. Italy
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.11. United Kingdom
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.11.4. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.6. United Kingdom Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.11.7. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.12. France
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.12.4. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.6. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.12.7. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.13. Russia
      • 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.13.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.14. Netherlands
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.16. Poland
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.17. Rest of Europe
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Gastroparesis Treatment Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.9. India
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.9.4. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.6. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.9.7. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.10. China
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.10.4. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.6. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.10.7. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.14. Thailand
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.15. Indonesia
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Gastroparesis Treatment Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Gastroparesis Treatment Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Gastroparesis Treatment Industry

  • 13.1. Competitive Dashboard
    • 13.1.1. Competitive Benchmarking
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. Medtronic plc
    • 13.2.2. Abbott Laboratories
    • 13.2.3. Salix Pharmaceuticals, Inc.
    • 13.2.4. Kimberly-Clark Corporation
    • 13.2.5. C. R. Bard, Inc
    • 13.2.6. Boston Scientific Corporation
    • 13.2.7. Janssen Global Services LLC
    • 13.2.8. Alfa Wassermann SPA
    • 13.2.9. AbbVie Inc.
    • 13.2.10. Evoke Pharma
    • 13.2.11. Cardinal Health, Inc.
    • 13.2.12. Rhythm Pharmaceuticals, Inc.
    • 13.2.13. GlaxoSmithKline Plc
    • 13.2.14. Bausch Health
    • 13.2.15. Neurogastrx, Inc.
    • 13.2.16. Theravance Biopharma
    • 13.2.17. AstraZeneca Plc
    • 13.2.18. Cipla Limited
    • 13.2.19. Pfizer, Inc.
    • 13.2.20. Teva Pharmaceutical Industries Limited
    • 13.2.21. The Takeda Pharmaceutical Company Ltd.
    • 13.2.22. Processa Pharmaceuticals, Inc.
    • 13.2.23. Vanda Pharmaceuticals, Inc.
    • 13.2.24. Otsuka Holdings Co. Ltd.
    • 13.2.25. ANI Pharmaceuticals, Inc.
    • 13.2.26. CinDome Pharma, Inc.
    • 13.2.27. PTC Therapeutics
    • 13.2.28. Ironwood Pharmaceuticals, Inc.
    • 13.2.29. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us